CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OMEPRAZOLE ASSAY/		*USP37–NF32*	4067	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SUSPENSION	*Procedure*							*Solution A*: Change with dilute phosphoric acid to: with dilute sodium hydroxide
POWDERED HOLY BASIL LEAF EXTRACT	COMPOSITION /*Content of Triterpenes*	*USP37–NF32*	5458	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of *Standard solution B*: Change 0.45-?L to: 0.45-?m
ALCOHOL IN DEXTROSE INJECTION	ASSAY/ *Dextrose*	*USP37–NF32*	1637	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 15 of *Analysis*: Change *A* = length of the polarimeter tube (mm) to: *A* = 100 mm divided by the length of the polarimeter tube (mm)
PYRANTEL PAMOATE	ASSAY/ *Procedure*	*USP37–NF32*	4491	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change acetic acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								glacial acetic acid AND Line 1 of *Column efficiency*: Change NLT 8000 theoretical plates to: NLT 8000 theoretical plates for the pyrantel peak
CARBAMAZEPINE EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*USP37–NF32*	2123	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Sample stock solution B*: Change *Standard stock solution* to: *Sample stock solution A*
RIBAVIRIN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*/ *Procedure 1*/	*USP37–NF32*	4562	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Column*: Change 7-µm packing L17 to: 9-µm packing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Chromatographic system							L17
DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS	IMPURITIES/*Limit of Ibuprofen Related Compound C*	*USP37–NF32*	2651	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Analysis*: Change R_U = peak area ratio of ibuprofen to valerophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to valerophenone from the *Standard solution* to: R_U = peak area ratio of ibuprofen related compound C to valerophenone from the *Sample solution* R_S = peak area ratio of ibuprofen related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound C to valerophenone from the *Standard solution*
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION	ASSAY/ *Procedure*	*USP37–NF32*	4766	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Sample stock solution*: Change sulfacetamide to: sulfacetamide sodium AND Line 1 of *Sample solution*: Change sulfacetamide to: sulfacetamide sodium
GRISEOFULVIN CAPSULES	PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>*/ *Procedure for content uniformity*	*USP37–NF32*	3196	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *Analysis*: Change Result = $(A_U/A_S) \times (C_S/C_U) \times P \times 100$ to: Result = (*A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/A_S$) × (C_S/C_U) × *P* × *F* × 100 AND After *P* in definition list: Add *F* = conversion factor, 0.001 mg/?g
VALSARTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5115	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of USP Valsartan Related Compound A RS: Change (*R*)-*N*-Valeryl-*N*-([2?-(1*H*-tetrazole-5-yl)biphen-4-yl]methyl)valine. to: *N*-Valeryl-*N*-{[2?-(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 2 of USP Valsartan Related Compound B RS: Change (*S*)-*N* -Butyryl -*N* -([2?-(1*H* -tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N* -Butyryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine. AND Line 2 of USP Valsartan Related Compound C RS: Change (*S*)-*N* -Valeryl -*N*-([2'-(1*H* -tetrazole-5-yl)biphen-4-yl]methy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l)-valine benzyl ester. to: *N* -Valeryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.
LAMIVUDINE AND ZIDOVUDINE TABLETS	IM PURITIES/*Organic Impurities*	*USP37–NF32*	3484	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 12 of *Analysis*: Change unidentified impurity to: unspecified impurity AND Line 19 of *Analysis*: Change unidentified impurities to: unspecified impurities
POWDERED ECHINACEA PALLIDA	ADDITIONAL REQUIREMENTS/*USP*	*USP37–NF32*	5356	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							*purpurea* Extract RS to: USP Powdered *Echinacea pallida* Extract RS
NYSTATIN	DEFINITION	*USP37–NF32*	4035	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6: Change extemporaneous solution to: extemporaneous preparation
HOLY BASIL LEAF	COMPOSITION */Content of Triterpenes*	*USP37–NF32*	5454	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of *Standard solution B*: Change 0.45-?L to: 0.45-?m
DESCRIPTION AND SOLUBILITY	*Sodium Acetate*	*USP37–NF32*	1525	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 7: Change transfer liquid. to: transfer ligand.
PROGESTERONE VAGINAL SUPPOSITORIES	ASSAY/ *Suppositories in Fatty Acid Base*	*USP37–NF32*	4430	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *System suitability solution*: Change Transfer 2.0 mL of *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability stock solution A and *System suitability stock solution B* to: Transfer 2.0 mL of each *System suitability stock solution A* and *System suitability stock solution B* AND Line 2 of *Standard solution A*: Change Mix 5.0 of the solution to: Mix 5.0 mL of the solution
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*First Supplement to USP37–NF32*	6619	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Standard solution*: Change 0.56 mg/mL of USP Ciprofloxacin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride RS in *Medium* to: 0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in *Medium* AND Line 8 of *Analysis*: Change C_S = concentration of ciprofloxacin in the *Standard solution* (mg/mL) to: C_S = concentration of ciprofloxacin hydrochloride in the *Standard solution* (mg/mL)
AMINOSALICYLATE SODIUM	ASSAY/ *Procedure*	*USP37–NF32*	1745	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 15 of *Analysis*: Change C_U = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								aminosalicylate in the *Sample solution* (mg/mL) to: C_U = concentration of Aminosalicylate Sodium in the *Sample solution* (mg/mL)
QUINIDINE GLUCONATE	DEFINITION	*USP37–NF32*	4512	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6: Change quinidine sulfate to: quinidine gluconate
CODEINE PHOSPHATE ORAL SOLUTION	ASSAY/ *Procedure*	*USP37–NF32*	2451	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times 100$ to: Result = $(R_U/R_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND After C_U in definition list: Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								M_{r1} = molecular weight of codeine phosphate hemihydrate, 406.37 M_{r2} = molecular weight of anhydrous codeine phosphate, 397.37
SUFENTANIL CITRATE INJECTION	ASSAY/ *Procedure*	*USP37–NF32*	4759	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 11 of *Analysis*: Change sufentanil to: sufentanil citrate
FOSPHENYTOIN SODIUM INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	3096	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Before USP Fosphenytoin Sodium RS: Add USP Endotoxin RS
TRIACETIN	ASSAY/ *Procedure/Titrimetric system*	*USP37–NF32*	5031	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change (See *Titrimetry <541>, Residual Titrations*.) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(See *Titrimetry <541>*.) AND Line 1 of *Mode*: Change Direct titration to: Residual titration
HYDROCHLOROTHIAZIDE TABLETS	IMPURITIES/*Organic Impurities*	*USP37–NF32*	3247	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 11 of *Analysis*: Change C_U = concentration of the *Sample solution* (?g/mL) to: C_U = nominal concentration of hydrochlorothiazide in the *Sample solution* (?g/mL)
POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5350	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea purpurea* Extract RS to: USP Powdered *Echinacea*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								angustifolia Extract RS
ONDANSETRON INJECTION	*Assay*	*Second Supplement to USP36–NF31*	Online	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change (293.36 / 329.82)(25*C* / *V*)(r_U / r_S) to: (293.36 / 329.83)(25*C* / *V*)(r_U / r_S) AND Line 8 of *Procedure*: Change 329.82 to: 329.83
MAGNESIUM ALUMINUM SILICATE	IMPURITIES/*Arsenic, Method I <211>*	*USP36–NF31*	2073	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Standard preparation*: Change Prepare as directed in the chapter. to: Transfer 5.0 mL (5 ?g of arsenic) of the *Standard Arsenic Solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Delete: *Control preparation*: Transfer 5.0 mL (5 ?g of As) of the *Standard preparation* to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Line 1 of *Acceptance criteria*: Change the absorbance due to any red color from the *Test preparation* does not exceed that

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								produced by the *Control preparation*. to: the absorbance due to any red color from the *Test preparation* does not exceed that produced by the *Standard preparation*.
SODIUM ACETATE	IM PUR ITIES/*Inorganic Impuri ties*/*Potassium*	*USP36–NF31*	5147	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS	ASSAY	*Second Supplement to USP36–NF31*	6580	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	*Analysis*: Change To 5 mL of *Sample solution* add to: To the *Sample solution* add Line 2 of *Procedure*: Change Inject the *Sample solution* within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light.
ANTIBIOTICS—MICROBIAL ASSAYS	Turbidimetric Method	*USP36–NF31*	76	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 9 of Paragraph 2 of *Analysis*: Change or a water bath maintained at the temperature

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								specified in *Table 8* and for the time specified in *Table 11*. to: or a water bath maintained at 36.0° –37.5° for the time specified in *Table 11*.
ONDANSETRON ORAL SOLUTION	*Related compounds*	*USP36–NF31*	4586	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change $(293.36/329.82)10{,}000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)$ to: $(293.36 / 329.83)10{,}000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)$ AND Line 8 of *Procedure*: Change 329.82 to: 329.83

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATROPINE SULFATE INJECTION	ASSAY/ *Procedure*	*First Supplement to USP36–NF31*	5950	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Buffer*: Change Dissolve 4.1 g of sodium acetate and to: Dissolve 4.1 g of anhydrous sodium acetate and
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	COMPOUNDING FACILITIES	*Revision Bulletin (Official January 01, 2014)*	Online	28-Mar-2014	1-Apr-2014	*Second Supplement to USP37–NF32*	*Second Supplement to USP37–NF32*	Line 4 of Paragraph 4: Change (see the *General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity*; to: (see *Packaging and Storage Requirements <659>*;
CLINDAMYCIN PALMITATE HY	ASSAY/ *Procedure*	*USP36–NF31*	3031	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Acceptance*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORIDE								*criteria*: Change NLT 540 ?g to: NLT 540 ?g/mg
THALIDOMIDE CAPSULES	*Dissolution <711>*	*USP36–NF31*	5347	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	After the *Test solution* section: Add to: *Chromatographic system*—Prepare as directed in the *Assay* under *Thalidomide*.
CALCIUM SULFATE	ASSAY/ *Procedure*	*First Supplement to USP36–NF31*	Online	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 14 of *Analysis*: Change Result = [(*V* × *N* × *F*)/*W*] × 100 to: Result = [(*V* × *M* × *F*)/*W*] × 100 AND Line 15 of *Analysis*: Change *V* = volume of titrant consumed by the Sample (mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N = actual normality of the titrant (mEq/mL) *F* = equivalency factor, 136.14 mg/mEq to: *V* = volume of *Titrant* consumed by the *Sample* (mL) *M* = actual molarity of the *Titrant* (mM/mL) *F* = equivalency factor, 136.14 mg/mM
Sodium Sulfite, Anhydrous	RE AGENTS/*Reagent Specifications*	*USP36–NF31*	1196	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change [7753-83-7] to: [7757-83-7]
ONDANSETRON ORAL SOLUTION	*Assay*	*USP36–NF31*	4586	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change (293.36/329.82)100(*C*/*V*)(r_U / r_S) to: (293.36 / 329.83)100(*C* / *V*)(*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$/ r_S) AND Line 8 of *Procedure*: Change 329.82 to: 329.83
BUTYLPARABEN	IMPURITIES/*Related Substances*/*Chromatographic system*	*Second Supplement to USP36–NF31*	6551	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	After the *Column* section: Add *Column temperature*: 35°
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	STABILITY CRITERIA AND BEYOND-USE DATING/*General Guidelines for Assigning Beyond-Use Dates*	*Revision Bulletin (Official January 01, 2014)*	Online	28-Mar-2014	1-Apr-2014	*Second Supplement to USP37–NF32*	*Second Supplement to USP37–NF32*	Line 7 of Paragraph 1: Change (see the *General Notices and Requirements, Preservation, Packaging, Storage, and Labeling*) to: (see <659>)
MELPHALAN TABLETS	*Dissolution <711>*	*USP36–NF31*	4232	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change Prepare a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1 500:500:2:2:0.4). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). to: Transfer 2 grams of ammonium acetate, 2 mL of glacial acetic acid, and 0.4 mL of triethylamine to a suitable flask containing 1500 mL of water and 500 mL of acetonitrile. Stir

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								until all solids are dissolved and well mixed, then filter and degas.
THIMEROSAL	IM PURITIES/*Mercury Ions*	*USP36–NF31*	5368	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 19 of *Analysis*: C_S = concentration of mercuric chloride in the *Standard solution* (mg/mL) to: C_S = concentration of mercuric chloride in *Sample solution B* (mg/mL)
CLARITHROMYCIN	ASSAY/*Procedure*/*System suitability*	*USP36–NF31*	3016	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Samples*: Change *Standard solution 2* and *Standard solution 4* to: *Standard solution 1*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution 2, and *Standard solution 4* AND Line 13 of *Suitability requirements*: Change *Relative standard deviation*: NMT 1.5%, *Standard solution 2* to: *Relative standard deviation*: NMT 1.5%, *Standard solution 1*
RISPERIDONE TABLETS	*Dissolution <711>*	*USP36–NF31*	5065	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 4 of *Chromatographic system*: Change Chromatograph the *Standard solution* and the *Test solution* as directed for *Procedure*: to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATOMOXETINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 2*	*First Supplement to USP36–NF31*	5947	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Chromatograph the *Standard solution* as directed for *Procedure*: Line 5 of *System suitability solution*: Change dissolving the Reference Standards in ethanol, to: dissolving the Reference Standards in absolute alcohol, AND Line 2 of *Sample solution*: Change dissolving it in ethanol, to: dissolving it in absolute alcohol,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION	CONTAMINANTS	*Second Supplement to USP36–NF31*	6399	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Add the test: *Absence of Specified Microorganisms* <2022>: Meet the requirements of the tests for the absence of *Salmonella species*, *Escherichia coli*, and *Staphylococcus aureus*
CANDESARTAN CILEXETIL	ASSAY/ *Procedure*	*USP36–NF31*	2774	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Analysis*: Change Titrate with 8 mL of 0.1 N to: Titrate with 0.1 N
FENTANYL	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP36–NF31*	3554	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Footnote f of Table 2: Change *N*-Phenyl-*N*-[1-(2-phenylethyl)-4-piperidinyl]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetanilide hydrochloride, or acetyl fentanyl. to: *N* -(1-Phenethylpiperidin-4-yl)-*N* -phenylacetamide.
VANCOMYCIN HYDROCHLORIDE FOR INJECTION	SPECIFIC TESTS/*Content of Vancomycin*	*USP36–NF31*	5546	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 27 of *Analysis*: Change Result = $[r_I/(D \times r_B) + r_A] \times 100$ to: Result = $\{r_I/[(D \times r_B) + r_A]\} \times 100$
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH/ *Molybdenum, Method 1*	*Second Supplement to USP36–NF31*	6372	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Standard solutions*: Change 2.0 to: 5.0

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- …
- Next page Next ›
- Last page Last »